News und Analysen
Premier, Inc. to Participate in Piper Sandler 34th Annual Healthcare Conference on November 30, 2022
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in a fireside chat at the
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
Novocure (NASDAQ: NVCR) announced today it will participate in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022. William Doyle, Novocure’s Executive Chairman, and Ashley
Acadia Healthcare to Host Investor Day
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will host its first Investor Day on Wednesday, December 7, 2022, in New York City.
The presentation and Q&A session
LivaNova Receives 510(k) Clearance for ECMO from FDA for LifeSPARC, the Next-generation Advanced Circulatory Support System
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the U.S
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
Novocure (NASDAQ: NVCR) today announced 25 abstracts on Tumor Treating Fields (TTFields) therapy will be featured at the Society for Neuro-Oncology (SNO) 2022 Annual Meeting from Nov. 16 to Nov. 20
Novocure Secures CE Mark for New Array
Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor Treating Fields delivery and greater
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that
Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the
LivaNova to Present at the Stifel, Wolfe and Piper Sandler Healthcare Conferences
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its Chief Executive Officer Damien McDonald will present a general business update during
Acadia Healthcare Set to Open Four New Comprehensive Treatment Centers
Acadia Healthcare, a leading provider of behavioral healthcare services, is accepting new patients at its four new Comprehensive Treatment Centers (CTCs) in Georgia.
This press release features
Acadia Healthcare Acquires Four CTC Facilities in Georgia
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the recent acquisition of four comprehensive treatment centers (“CTC”) from Georgia-based Brand New Start Treatment Centers. The four
Xencor Reports Third Quarter 2022 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced topline
Acadia Healthcare to Participate in Credit Suisse 31st Annual Healthcare Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the Credit Suisse 31st Annual Healthcare Conference, November 7 - 10, 2022, at Terranea Resort in
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that
Premier Inc. to Participate in Credit Suisse 31st Annual Healthcare Conference on November 8, 2022
Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in a fireside chat at the
LivaNova Reports Third-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2022.
Financial Summary and Highlights1
Premier, Inc. Reports Fiscal Year 2023 First Quarter Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2023 first quarter ended September 30, 2022.
"Our
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will
Novocure Reports Third Quarter 2022 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
Novocure (NASDAQ: NVCR) today announced 11 poster presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting from
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology
Novocure (NASDAQ: NVCR) today announced a review article of anti-cancer mechanisms of action of Tumor Treating Fields (TTFields) has been published in the Journal of Molecular Cell Biology (JMCB).
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
Novocure (NASDAQ: NVCR) today announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a distinct anticancer modality and an